The estimated Net Worth of Hans T. Schambye is at least 1.33 百万$ dollars as of 22 March 2022. Dr Schambye owns over 5,000 units of Galecto stock worth over 687,855$ and over the last 4 years he sold GLTO stock worth over 0$. In addition, he makes 644,982$ as Co-Founder、 Pres、 CEO & Director at Galecto.
Sign up
Dr Schambye GLTO stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Galecto stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of GLTO stock worth 10,750$ on 22 March 2022.
The largest trade he's ever made was buying 5,000 units of Galecto stock on 22 March 2022 worth over 10,750$. On average, Dr trades about 1,563 units every 34 days since 2020. As of 22 March 2022 he still owns at least 52,428 units of Galecto stock.
You can see the complete history of Dr Schambye stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Hans T. Schambye biography
Dr. Hans T. Schambye is the Co-Founder, Pres, CEO & Director at Galecto.
What is the salary of Dr Schambye?
As the Co-Founder、 Pres、 CEO & Director of Galecto, the total compensation of Dr Schambye at Galecto is 644,982$. There are no executives at Galecto getting paid more.
How old is Dr Schambye?
Dr Schambye is 55, he's been the Co-Founder、 Pres、 CEO & Director of Galecto since . There are 2 older and 2 younger executives at Galecto. The oldest executive at Galecto Inc. is Prof. Bertil Lindmark M.D., Ph.D., 66, who is the Chief Medical Officer.
What's Dr Schambye's mailing address?
Hans's mailing address filed with the SEC is OLE MAALOES VEJ 3, C/O GALECTO, INC., COPENHAGEN N G7, G7, DK-2200.
Insiders trading at Galecto
Over the last 4 years, insiders at Galecto have traded over 2,298,261$ worth of Galecto stock and bought 1,911,769 units worth 28,139,830$ . The most active insiders traders include Holdings A/S Novo、Chau Quang Khuong、Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of 2,037,418$. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth 617,010$.
What does Galecto do?
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
What does Galecto's logo look like?
Complete history of Dr Schambye stock trades at Galecto
Galecto executives and stock owners
Galecto executives and other stock owners filed with the SEC include:
-
Dr. Hans T. Schambye,
Co-Founder, Pres, CEO & Director -
Prof. Bertil Lindmark M.D., Ph.D.,
Chief Medical Officer -
Anders Pedersen,
Chief Operating Officer -
Dr. Stephanie Oestreich Ph.D.,
Chief Bus. Officer -
Garrett Winslow,
Sr. VP & Gen. Counsel -
Jonathan P. Freve CPA, CPA,
Chief Financial Officer -
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP,
Co-Founder & Member of the Clinical Advisory Board - IPF -
Dr. Hakon Leffler,
Co-Founder -
Ulf J. Nilsson,
Co-Founder -
Advisors Llc Orbi Med Genes...,
-
Holdings A/S Novo,
10% owner -
Carl Goldfischer,
-
Anders Pedersen,
Chief Operating Officer -
Hans T. Schambye,
Chief Executive Officer -
Stephan Christgau,
Director -
Advisors Llc Orbi Med Advis...,
-
Bertil Lindmark,
Chief Medical Officer -
Jonathan Freve,
Chief Financial Officer -
Chau Quang Khuong,
Director -
Stephanie Oestreich,
Chief Business Officer -
Jayson Donald Alexander Dallas,
-
Amit Munshi,
-
Anne Prener,
-
David Shapiro,
-
Garrett Winslow,
General Counsel